A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, discuss why recent regulatory actions could mark an inflection point for psychedelic psychiatry.
Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, discuss why recent regulatory actions could mark an inflection point for psychedelic psychiatry.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
New randomized controlled trial data presented at ASAM 2026 highlighted the benefits of integrating Written Exposure Therapy (WET) into residential substance use disorder (SUD) treatment.
New randomized controlled trial data presented at ASAM 2026 highlighted the benefits of integrating Written Exposure Therapy (WET) into residential substance use disorder (SUD) treatment.
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
At the American Society of Addiction Medicine (ASAM) 2026 Annual Conference, hosted in San Diego on April 23-26, 2026, clinicians will explore numerous emerging strategies addressing substance use disorders (SUDs)
At the American Society of Addiction Medicine (ASAM) 2026 Annual Conference, hosted in San Diego on April 23-26, 2026, clinicians will explore numerous emerging strategies addressing substance use disorders (SUDs)
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
A large US longitudinal study published in Neuropsychopharmacology found that adolescents who initiated cannabis use showed flatter neurocognitive development over time than peers who did not use cannabis.
A large US longitudinal study published in Neuropsychopharmacology found that adolescents who initiated cannabis use showed flatter neurocognitive development over time than peers who did not use cannabis.
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
From identifying patients’ life goals to addressing misconceptions, the LAI-CARE healthcare professional module outlines key moments in the long-acting injectable antipsychotics (LAIs) discussion. Explore guidance on presenting options, explaining features in supportive language, and revisiting LAIs when appropriate. It provides a framework for navigating these conversations with intention.
Dr Greg Mattingly, Dr Rakesh Jain, Dr Andrew Cutler, and Desiree Matthews, PMHNP-BC, examine key limitations in today’s ADHD care. Learn why emotional dysregulation and executive dysfunction continue to be overlooked and how that affects patient outcomes. Stream the series today!
Explore practical resources, including pediatric scales and quick guides, to support structured symptom evaluation and tracking in bipolar mania and schizophrenia. Learn more today!
ABBV-US-02406-MC, V1.0 | Approved 04/2026 | AbbVie Medical Affairs
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Recent research highlights how targeted communication strategies may improve treatment acceptance in patients with mental illness or tardive dyskinesia (TD).
Recent research highlights how targeted communication strategies may improve treatment acceptance in patients with mental illness or tardive dyskinesia (TD).
Psych Congress NP Institute Co-Chair Andrew Penn, MS, PMHNP-BC, shares practical guidance for psychiatric nurse practitioners building long-term careers in mental health care settings.
Psych Congress NP Institute Co-Chair Andrew Penn, MS, PMHNP-BC, shares practical guidance for psychiatric nurse practitioners building long-term careers in mental health care settings.
Experts highlighted the clinical and neurobiological overlap between sleep disturbances and psychiatric conditions at the 2026 NP Institute in Nashville.
Experts highlighted the clinical and neurobiological overlap between sleep disturbances and psychiatric conditions at the 2026 NP Institute in Nashville.
New data presented in a poster at the 2026 Psych Congress NP Institute in Nashville, TN, highlight the efficacy and safety of AXS-05 (dextromethorphan-bupropion) based on results from the Phase 2/3 ADVANCE-1 and Phase 3 ACCORD-1 randomized...
New data presented in a poster at the 2026 Psych Congress NP Institute in Nashville, TN, highlight the efficacy and safety of AXS-05 (dextromethorphan-bupropion) based on results from the Phase 2/3 ADVANCE-1 and Phase 3 ACCORD-1 randomized...
The fourth annual Psych Congress NP Institute aims to equip psychiatric nurse practitioners with the tools and clinical strategies needed to navigate an increasingly complex care landscape.
The fourth annual Psych Congress NP Institute aims to equip psychiatric nurse practitioners with the tools and clinical strategies needed to navigate an increasingly complex care landscape.
In this Q&A, Brooke Kempf, PMHNP-BC, Steering Committee, Psych Congress, and Jonathan Meyer, MD, Consultant, Psych Congress, outline the hallmark characteristics of DIP and TD.
In this Q&A, Brooke Kempf, PMHNP-BC, Steering Committee, Psych Congress, and Jonathan Meyer, MD, Consultant, Psych Congress, outline the hallmark characteristics of DIP and TD.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
Adherence concerns. Relapse risk. Shifting treatment goals. Decisions made in one setting often have implications in the next. S.C.O.P.E. presents real clinical dilemmas across emergency, inpatient, and outpatient schizophrenia care, allowing clinicians to examine how long-acting injectables (LAIs) may be considered at pivotal moments within evolving treatment pathways.
The RMS website introduces the RMS, a brief tool developed to support the differentiation of bipolar I disorder from major depressive disorder. Access educational content, the screening tool, and a guided patient case experience to help reinforce clinical reasoning. View now!
ABBV-US-02404-MC, V1.0 | Approved 04/2026 | AbbVie Medical Affairs
The Partner Spotlight is a centralized hub for attention-deficit/hyperactivity disorder (ADHD) education, bringing together guides, videos, articles, and tools focused on a nonstimulant treatment option. Content is thoughtfully curated, updated regularly, and designed to stay relevant to patient-facing care as needs evolve. See what the Partner Spotlight page has to offer.
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA; Ragy R. Girgis, MD, MS
In this episode, Drs Rakesh Jain and Craig Chepke are joined by Dr Ragy Girgis of Columbia University to explore the small but important nuances around antidepressants, black box warnings, and violence risk in untreated psychosis.
In this episode, Drs Rakesh Jain and Craig Chepke are joined by Dr Ragy Girgis of Columbia University to explore the small but important nuances around antidepressants, black box warnings, and violence risk in untreated psychosis.
Sleep–wake disorders are clinically significant and too often overlooked in psychiatric practice. Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating insomnia, hypersomnia, and obstructive sleep apnea.
Sleep–wake disorders are clinically significant and too often overlooked in psychiatric practice. Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating insomnia, hypersomnia, and obstructive sleep apnea.
In this episode, Drs Rakesh Jain and Craig Chepke explore why fibromyalgia belongs in psychiatry’s wheelhouse and address the stigma patients face every day.
In this episode, Drs Rakesh Jain and Craig Chepke explore why fibromyalgia belongs in psychiatry’s wheelhouse and address the stigma patients face every day.
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in front of us.
Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in front of us.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
